Clinical trial • Phase III • Infectious Disease
Clinical trial in COVID-19 (SARS-CoV-2) booster vaccination
Phase III trial for COVID-19 (SARS-CoV-2) booster vaccination. 20 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- COVID-19 (SARS-CoV-2) booster vaccination
- Trial Stage
- Phase III
- Drug Modality
- Vaccine
Key dates
- Initial CTIS Submission Date
- 22-09-2025
- First CTIS Authorization Date
- 17-12-2025
Trial design
Phase III trial across 1 site in Finland.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 8
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Finland
- Earliest CTIS Part Ii Submission Date
- 20-11-2025
- Latest Decision Or Authorization Date
- 17-12-2025
- Processing Time Days
- 27
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Pohjois-Savon hyvinvointialue
- Department Name
- Kuopio University Hospital, Department of Otorhinolaryngology
- Contact Person Name
- Heikki Löppönen
- Contact Person Email
- heikki.lopponen@uef.fi
Sponsor
Primary sponsor
- Full Name
- Rokote Laboratories Finland Oy
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Finland
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection